[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100655072":3},{"organization":4,"outcomesModule":7,"designInfo":17,"detailedDescription":11,"studyPopulation":20,"armGroups":21,"interventions":30,"overallOfficials":39,"centralContacts":44,"locations":50,"responsibleParty":63,"collaborators":11,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":11,"eligibilityCriteria":71,"healthyVolunteers":72,"sex":73,"minAge":74,"maxAge":11,"enrollmentInfo":75,"targetDuration":11,"studyType":78,"phases":11,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":87,"whyStopped":11,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"CanSino Biologics Inc.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9,13,15],{"measure":10,"description":11,"timeFrame":12},"Positivity rate of IgG antibodies against tetanus toxoid.",null,"2.5 years after vaccination",{"measure":14,"description":11,"timeFrame":12},"Geometric mean concentration (GMC) against tetanus toxoid.",{"measure":16,"description":11,"timeFrame":12},"The proportion of antibody concentrations ≥ 1.0 IU\u002FmL 2.5 years after vaccination.",{"allocation":11,"interventionModel":11,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":18,"timePerspective":19,"maskingInfo":11},"COHORT","PROSPECTIVE","This study included 240 participants who had previously taken part in a Phase III clinical trial of the adsorbed tetanus vaccine (Protocol No.: CTP-TTVA-001), with 120 participants in each of the treatment and control groups.",[22,26],{"label":23,"type":11,"description":11,"interventionNames":24},"Previously vaccinated with Tetanus Vaccine, Adsorbed (TTVA)",[25],"Other: Previously vaccinated with TTVA",{"label":27,"type":11,"description":11,"interventionNames":28},"Previously vaccinated with Tetanus Vaccine, Adsorbed (TT)",[29],"Other: Previously vaccinated with TT",[31,36],{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":11},"OTHER","Previously vaccinated with TTVA","3.0 to 4.0 mL of venous blood will be collected for the immunodynamic study.",[23],{"type":32,"name":37,"description":34,"armGroupLabels":38,"otherNames":11},"Previously vaccinated with TT",[27],[40],{"name":41,"affiliation":42,"role":43},"Qiuyue Mu","Guizhou Center for Disease Control and Prevention","PRINCIPAL_INVESTIGATOR",[45],{"name":46,"role":47,"phone":48,"phoneExt":11,"email":49},"Shunda Zhang","CONTACT","022-58213600-6051","shunda.zhang@cansinotech.com",[51],{"facility":52,"status":11,"city":53,"state":54,"zip":11,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":11},"Center for Disease Control and Prevention, Qixingguan District, Bijie City","Bijie","Guizhou","China","CN",{"type":58,"coordinates":59},"Point",[60,61],105.28627,27.30193,{"lat":61,"lon":60},{"type":64,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100655072","observation-of-immune-persistence-in-a-clinical-trial-of-an-adsorbed-tetanus-vaccine-100655072",false,"NCT07807033","Observation of Immune Persistence in a Clinical Trial of an Adsorbed Tetanus Vaccine","Observation of Immune Persistence in a Phase III Clinical Trial of an Adsorbed Tetanus Vaccine","Inclusion Criteria:\n\n* Individuals who have previously participated in the Phase III clinical trial of the adsorbed tetanus vaccine (Protocol No.: CTP-TTVA-001).\n* Willing to provide identification documents.\n* Have given informed consent, voluntarily signed the informed consent form, and are able to comply with the requirements of the clinical trial protocol.\n* At least 2.5 years have elapsed since completion of the vaccination series.\n\nExclusion Criteria:\n\n* Following vaccination in the Phase III clinical trial (Protocol No.: CTP-TTVA-001), participants who have received tetanus immunoglobulin, tetanus antitoxin, or a vaccine containing tetanus toxoid antigen.\n* Participants in the previous Phase III clinical trial (Protocol No.: CTP-TTVA-001) who did not complete the blood draw 30 days after vaccination.\n* Other circumstances deemed by the investigator to render a participant ineligible for this clinical study.",true,"ALL","18 Years",{"count":76,"type":77},240,"ESTIMATED","OBSERVATIONAL","This study included 240 trial participants who had previously taken part in a Phase III clinical trial of an adsorbed tetanus vaccine (Protocol No.: CTP-TTVA-001), with 120 participants in each of the treatment and control groups. All trial participants were required to provide 3.0-4.0 mL of blood for an immunodurability assessment 2.5 years after vaccination.",[81],"Tetanus",[83,84,85,86],"Vaccine","≥18years","Positive-controlled","Immune Persistence","NOT_YET_RECRUITING","2026-09-02",{"date":90,"type":91},"2026-09-08","ACTUAL",{"date":93,"type":77},"2026-10-15",{"date":95,"type":77},"2026-11-15",{"name":5,"class":6},1]